Treatment of advanced solid tumors using CD70-targeting CAR-T cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and efficacy of CHT101, an allogeneic CAR-T cell therapy targeting CD70, in patients with advanced solid tumors that express CD70. The study consists of a dose escalation phase with four planned cohorts, followed by a dose expansion phase after a safety review. Participants will be monitored for safety, pharmacokinetics, and preliminary efficacy data throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to understand and sign a written informed consent documen；
2. At the date of signing ICF, 18 \~70 years old, male or female；
3. Histopathological confirmed advanced or metastatic solid tumors patients who have failed to standard treatment or intolerance with standard treatment；
4. Positive CD70 expression;
5. At least one measurable lesion at baseline per RECIST version 1.1；
6. The expected survival time is more than 12 weeks;
7. ECOG 0-1 points;
8. Adequate organ functions;

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Xin Yao, Ph.D
• Email: yaoxin1969@yahoo.com.cn
• Phone: +86-02223340123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hydrogel spacer to protect the rectum during cervical cancer radiotherapy

  This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07904182

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• Phase II test of SHR-A1811 for ultra-low HER2 advanced breast cancer

  This phase II trial tests SHR-A1811 in women with advanced breast cancer and ultra-low HER2 expression who have had 1-2 prior therapies.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07817082

• Risk-stratified management of inavolisib-induced hyperglycemia in breast cancer patients

  This observational study tests whether using a pre-treatment risk-stratified plan to manage high blood sugar from inavolisib helps patients stay on therapy.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07817056

• Stereotactic body radiation therapy for spinal metastases with epidural compression

  This study tests whether SBRT can safely help adults with spinal metastases that compress the spinal cord see if the treatment works in reducing issues from their cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07809672

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.